CSL - upcoming presentation should be well received

CSL will present numerous medical reports (ie > 20 scientific abstracts; 5 oral presentations) pertaining to its haemophilia portfolio of investigational as well as commercialised products at the annual International Society on Thrombosis and Haemostasis (ISTH) conference being held in Toronto, Canada between 20-25 June. Specifically, CSL will present pivotal clinical trial data for two of its late-stage, long-acting recombinant drugs- factor VIII SingleChain (rVIII-SingleChain) and factor IX albumin fusion protein (rIX-FP) for the treatment of haemophilia A and haemophilia B, respectively (a market opportunity worth US$7bn+ and US$1bn+, respectively). We believe CSL’s presentations at the upcoming ISTH conference will likely highlight promising data across its haemophilia programs that should be well-received by the market. (CSL, Add, price Target A$101.73)


1 stock mentioned

Scott Power
Senior Analyst
Morgans

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.